zonisamide
Selected indexed studies
- Zonisamide add-on therapy for focal epilepsy. (Cochrane Database Syst Rev, 2020) [PMID:32715463]
- The SANAD II study of the effectiveness and cost-effectiveness of levetiracetam, zonisamide, or lamotrigine for newly diagnosed focal epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial. (Lancet, 2021) [PMID:33838757]
- Zonisamide for essential tremor. (Cochrane Database Syst Rev, 2017) [PMID:28836659]
_Worker-drafted node — pending editorial review._
Connections
zonisamide is a side effect of
Sources
- Zonisamide add-on therapy for focal epilepsy. (2020) pubmed
- The SANAD II study of the effectiveness and cost-effectiveness of levetiracetam, zonisamide, or lamotrigine for newly diagnosed focal epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial. (2021) pubmed
- Zonisamide for essential tremor. (2017) pubmed
- Zonisamide in Parkinson's disease: a current update. (2021) pubmed
- Zonisamide. (1991) pubmed
- Zonisamide add-on therapy for focal epilepsy. (2018) pubmed
- Introduction to zonisamide. (2006) pubmed
- Zonisamide's Efficacy and Safety on Parkinson's Disease and Dementia with Lewy Bodies: A Meta-Analysis and Systematic Review. (2022) pubmed
- Zonisamide in the treatment of epilepsy. (2011) pubmed
- Lamotrigine versus levetiracetam or zonisamide for focal epilepsy and valproate versus levetiracetam for generalised and unclassified epilepsy: two SANAD II non-inferiority RCTs. (2021) pubmed